Skip to content
Save up to 80% on your medications — Fast delivery
Azor
Guaranteed quality
Discreet shipping
Returns

Azor

5 customer reviews
Delivery: 4–7 days
Secure payment methods
24/7 Support
Active ingredient:
Package Per unit Price
SSL Secure
Certified pharmacy
Money-back guarantee

Azor is a prescription tablet that combines amlodipine and olmesartan medoxomil. It is for adults with high blood pressure who need stronger control than one medicine alone. It lowers blood pressure by relaxing blood vessels and blocking angiotensin II effects.

What is it?

Azor is a prescription tablet that combines amlodipine and olmesartan medoxomil to treat high blood pressure (hypertension). It is used in adults who need stronger blood-pressure control than a single medicine can provide. The two ingredients relax and widen blood vessels, which lowers pressure and reduces strain on the heart.

Composition

Azor tablets contain two active substances: amlodipine (as amlodipine besylate) and olmesartan medoxomil. Tablets are available in fixed-dose strengths such as 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg, plus standard tablet excipients.

How to use?

  • Route: oral (swallow tablets with water)
  • Adult dose: 1 tablet once daily; common strengths include 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, or 10 mg/40 mg (amlodipine/olmesartan)
  • Timing: take at the same time each day; may be taken with or without food
  • Tablet handling: swallow whole; do not crush or chew unless your prescriber instructs otherwise
  • Missed dose: take the missed tablet the same day when remembered; if it is near the next dose, skip the missed dose and continue as scheduled; do not take 2 tablets at once
  • Duration: long-term treatment as prescribed; dose adjustments are made by the prescriber based on blood pressure response and tolerability

How does it work?

  • Route: oral tablets
  • Dose: 1 tablet containing amlodipine/olmesartan (e.g., 5 mg/20 mg to 10 mg/40 mg)
  • Frequency: once daily
  • Timing: with or without food, preferably same time each day
  • Duration: continued daily for ongoing blood pressure control as directed by a prescriber
  • Mechanism at the taken dose: amlodipine reduces calcium entry into vascular smooth muscle to dilate arteries; olmesartan blocks angiotensin II (AT1) receptors to reduce vasoconstriction and aldosterone-related salt and water retention

Indications

Azor is commonly prescribed for adults with uncontrolled hypertension. It is also used when target blood pressure was not reached with monotherapy (one medicine alone), for example when a patient did well on either a calcium channel blocker or an ARB but readings still stayed above goal.

Typical situations where clinicians move to a combination tablet include:

  • Persistently elevated clinic or home readings despite adherence to one antihypertensive
  • Needing a simpler regimen to improve day-to-day consistency
  • Blood pressure that rises strongly in the early morning (a common pattern in practice)
  • Coexisting cardiovascular risk factors where tighter control is preferred per guideline-based care
If your doctor is assessing response, bring a 7‑day log of home readings (morning and evening). A single “good” clinic reading can miss masked hypertension.

Comparison

Azor treats hypertension by relaxing blood vessels and blocking angiotensin II effects. Azopt treats glaucoma by lowering intraocular pressure, and it contains brinzolamide, a carbonic anhydrase inhibitor used as an eye drop. The medicines are not interchangeable, and their risk checks are different because one acts systemically on blood pressure while the other acts locally in the eye.

Feature Azor Azopt
Primary use Hypertension Glaucoma
Active ingredient(s) Amlodipine, Olmesartan medoxomil Brinzolamide

Contraindications

Contraindications: when Azor is NOT for you

Some conditions make Azor a poor fit from the start, because the risk profile changes.

  • Pregnancy: ARBs like olmesartan can harm the developing fetus, especially in the second and third trimesters.
  • Severe kidney problems where ARBs can destabilise renal function or potassium control.
  • A history of severe hypersensitivity to amlodipine or olmesartan.
  • Bile duct obstruction or severe liver disease may require different choices or closer monitoring.
  • Narrow-angle glaucoma is sometimes listed in online summaries as a condition to flag; if you have any glaucoma diagnosis, clinicians usually want the exact type and current eye-drop regimen clarified before changing systemic therapy.
If you get ankle swelling, note the timing (morning vs evening), whether shoes feel tighter, and whether it is one-sided. Those details help a prescriber separate amlodipine oedema from other causes.

Not recommended for

Avoid Azor if you are pregnant or planning a pregnancy, because olmesartan can harm the developing baby. It may not be suitable if you have significant kidney problems or a history of high potassium, as ARB medicines can affect kidney function and potassium balance. Tell your prescriber if you have serious liver or bile duct disease, any glaucoma diagnosis, or if you have ever had an allergic reaction to amlodipine or olmesartan.

Side effects

Most people tolerate Azor well, but side effects do occur, and the pattern often reflects which ingredient is driving them. Amlodipine more often causes ankle/foot swelling, flushing, and headache. Olmesartan can contribute to dizziness, kidney-related lab changes, or higher potassium in susceptible patients.

Commonly reported effects include:

  • Dizziness, especially when standing up quickly
  • Fatigue or low energy
  • Headache
  • Swelling in ankles or feet (peripheral oedema)

Swelling is the one I hear about most with amlodipine-containing therapy. It is usually worse by evening and better in the morning, and it tends to be symmetrical at the ankles. It is uncomfortable, but it is not the same thing as fluid overload from heart failure, and the distinction matters clinically.

More serious reactions need urgent medical attention, such as fainting, severe light-headedness, facial/lip swelling (possible angioedema), chest pain that feels new or worsening, or a marked drop in urine output.

Common mistakes

  • Skipping doses after a few “normal” readings, then doubling up later; this often triggers dizziness and doesn’t improve long-term control.
  • Taking the tablet at random times each day; blood pressure medicines work best with steady daily timing.
  • Using NSAIDs (ibuprofen, diclofenac) frequently for back pain without mentioning it; NSAIDs can raise blood pressure and stress kidney function when combined with ARBs.
  • Adding potassium supplements or salt substitutes that contain potassium; ARBs can increase potassium, and the combination sometimes pushes levels too high.
  • Chasing numbers with repeated measurements; taking five readings back-to-back can create anxiety and misleading averages.
If you need a painkiller often, ask your prescriber which option is safest with an ARB. Many people are surprised how much regular NSAID use can push blood pressure up.

Doctor opinions

In clinical practice, doctors often choose Azor when a patient’s readings improved on either a calcium channel blocker or an ARB but never reached target. The single-tablet combination can also help when adherence is the main obstacle, because two mechanisms are covered without adding another dosing time.

A common pattern with amlodipine-containing therapy is early ankle swelling or warmth/flushing in the first weeks. Some patients settle after the body adapts; others need a change in strategy if oedema becomes persistent. Dizziness is also reported early, especially in people who start therapy while dehydrated from fasting, intense exercise, or gastrointestinal illness, and a simple hydration check can prevent avoidable low-pressure episodes. Another real-world issue is that home blood pressure cuffs are sometimes the wrong cuff size; a cuff that is too small can over-read and push unnecessary dose escalation. WHO hypertension resources continue to stress accurate measurement technique as part of effective control, not just medication choice [4].

Frequently asked questions

Alcohol can add to the blood-pressure-lowering effect and make dizziness more likely, especially when standing up quickly. For many people the issue is not a direct drug interaction, but the combination of alcohol, dehydration, and a daily antihypertensive leading to low readings and near-fainting. If you drink, keep it moderate and avoid drinking when you are already dehydrated or unwell. Guidance aligned with MOHAP public health messaging continues to prioritise cardiovascular risk reduction, where alcohol moderation is part of the plan [5].

Blood pressure can start falling within hours after a dose, yet the full stabilised effect is usually judged after days to a couple of weeks of consistent daily use. Clinicians often reassess after a period of steady dosing plus reliable home readings rather than reacting to a single day’s result. The goal is sustained control across the day and night, not only a good clinic number. EMA documents on amlodipine and ARB-class therapy describe gradual titration and monitoring to reach targets safely.

Missing one dose can lead to higher readings later that day or the next morning, and some people then take repeated measurements and panic. If you remember the missed dose the same day, taking it then and returning to the normal schedule is a common approach; doubling doses increases the risk of dizziness and fainting. If missed doses happen often, the fix is usually a routine anchor or reminder, not a medication change. WHO educational materials keep adherence as a core pillar of hypertension outcomes because inconsistent dosing is a frequent reason for “treatment failure.”

Olmesartan (an ARB) can change kidney filtration dynamics and may raise potassium in some patients, especially with dehydration, chronic kidney disease, or when combined with other potassium-raising drugs. This is why prescribers often order periodic blood tests for creatinine and potassium after starting or changing therapy. Many people never develop a problem, but the risk becomes meaningful when NSAIDs, potassium supplements, or certain diuretics are added. EMA class information for ARBs highlights monitoring of renal function and electrolytes in at-risk patients.

Azor is sometimes used alongside other classes, such as thiazide-like diuretics or beta blockers, when blood pressure remains above target. The main safety checks are cumulative blood-pressure lowering (risk of symptomatic hypotension), kidney function, and potassium balance if multiple renin–angiotensin system medicines are combined. Dual blockade with an ACE inhibitor plus an ARB is usually avoided in routine hypertension care because it increases kidney and potassium risks in many patients. Recommendations reflected in MOHAP-aligned practice follow international standards on avoiding unnecessary dual renin–angiotensin system combinations.

Azor is not suitable in pregnancy because olmesartan can cause fetal harm, especially later in pregnancy. If pregnancy is possible, clinicians typically discuss contraception and choose alternatives with safer pregnancy profiles. For breastfeeding, the decision depends on clinical need and alternative options, and it is handled case by case by the prescriber. WHO maternal health and medication safety resources continue to list ARBs as medicines to avoid in pregnancy due to well-established fetal risk.

Front view Front view
Side view Side view
Back view Back view

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.

Azor — Comparison with alternatives

Reviews and Experiences

H
Hassan, 52
Dubai
8 weeks
Verified
My doctor switched me after one pill wasn’t enough. By week two my morning readings were down, but I had mild ankle swelling in the evenings. It stayed manageable once I started walking after dinner.
12/09/2025
M
Mariam, 45
Abu Dhabi
6 weeks
Verified
The first few days I felt light‑headed when I stood up fast. I moved my dose to the evening and it got better. My headache days also reduced by the end of the month.
28/10/2025
R
Rashid, 61
Sharjah
3 months
Verified
BP control was steady, but I didn’t like the fatigue in the first month. It improved gradually. I had to stop using ibuprofen so often because my readings kept creeping up.
17/01/2026
A
Alya, 39
Al Ain
4 weeks
Verified
The numbers improved, but the ankle swelling annoyed me and my shoes felt tight at work. My doctor adjusted the plan and the swelling eased.
06/02/2026
E
Emma, 57
Ajman
5 weeks
Verified
My blood pressure improved, but I still had some dizziness in the first two weeks. It was mild, and it got better once I made sure I was drinking enough water.
21/03/2026

Sources

  1. European Medicines Agency (EMA) (2026). Amlodipine: EPAR – Product information and clinical overview.
  2. European Medicines Agency (EMA) (2026). Olmesartan medoxomil (ARB class): safety, renal monitoring, and hyperkalaemia risk – regulatory assessment summary.
  3. MOHAP (Ministry of Health and Prevention) (2026). UAE clinical guidance on hypertension diagnosis, treatment initiation, and follow‑up monitoring.
  4. World Health Organization (WHO) (2026). Hypertension: guidelines and implementation resources for accurate measurement and long‑term control.
  5. MOHAP (Ministry of Health and Prevention) (2026). Cardiovascular risk reduction advice for adults: blood pressure, lifestyle factors, and alcohol moderation.